ATE529112T1 - 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten - Google Patents
1-(4-piperidinyl)benzimidazolone als histamin h3 antagonistenInfo
- Publication number
- ATE529112T1 ATE529112T1 AT03719770T AT03719770T ATE529112T1 AT E529112 T1 ATE529112 T1 AT E529112T1 AT 03719770 T AT03719770 T AT 03719770T AT 03719770 T AT03719770 T AT 03719770T AT E529112 T1 ATE529112 T1 AT E529112T1
- Authority
- AT
- Austria
- Prior art keywords
- benzimidazolone
- histamine
- piperidinyl
- antagonist
- Prior art date
Links
- BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 title 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37346702P | 2002-04-18 | 2002-04-18 | |
| PCT/US2003/011696 WO2003103669A1 (en) | 2002-04-18 | 2003-04-16 | 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE529112T1 true ATE529112T1 (de) | 2011-11-15 |
Family
ID=29736058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03719770T ATE529112T1 (de) | 2002-04-18 | 2003-04-16 | 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7220735B2 (de) |
| EP (1) | EP1494671B1 (de) |
| JP (2) | JP4563800B2 (de) |
| KR (1) | KR20040099449A (de) |
| CN (1) | CN100360130C (de) |
| AR (1) | AR040406A1 (de) |
| AT (1) | ATE529112T1 (de) |
| AU (1) | AU2003223631B2 (de) |
| CA (1) | CA2482551C (de) |
| IL (1) | IL164583A (de) |
| MX (1) | MXPA04010172A (de) |
| MY (1) | MY132566A (de) |
| NZ (1) | NZ535764A (de) |
| PE (1) | PE20040464A1 (de) |
| TW (1) | TW200305409A (de) |
| WO (1) | WO2003103669A1 (de) |
| ZA (1) | ZA200407985B (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| DK1499316T3 (da) * | 2002-04-18 | 2008-07-21 | Schering Corp | (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister |
| KR20040099449A (ko) * | 2002-04-18 | 2004-11-26 | 쉐링 코포레이션 | 히스타민 ｈ3 길항제로서의1-(4-피페리디닐)벤즈이미다졸론 |
| IL165862A0 (en) * | 2002-06-28 | 2006-01-15 | Euro Celtique Sa | Therapeutic piperazine derivatives useful for tre ating pain |
| US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| DE602004015269D1 (de) | 2003-04-23 | 2008-09-04 | Glaxo Group Ltd | Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten. |
| US20050119266A1 (en) * | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
| EP1695961A4 (de) * | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | Harnstoffderivative, verfahren zu deren herstellung und verwendung |
| WO2006004793A2 (en) * | 2004-06-28 | 2006-01-12 | Janssen Pharmaceutica Nv | Hetero isonipecotic modulators of vanilloid vr1 receptor |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| EP1853610A1 (de) * | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | N-phenyl-benzamid-derivate als sirtuin-modulatoren |
| EP1902046B1 (de) * | 2005-06-20 | 2009-12-02 | Schering Corporation | Als antagonisten von histamin h3 geeignete piperidinderivate |
| ATE450525T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten |
| EP1909797A4 (de) * | 2005-08-02 | 2013-02-27 | Neurogen Corp | Dipiperazinyl-ketone und damit verwandte analoge |
| CA2618370A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2007035703A1 (en) | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
| KR20080087833A (ko) * | 2005-12-21 | 2008-10-01 | 쉐링 코포레이션 | 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체 |
| EP1966143A2 (de) * | 2005-12-21 | 2008-09-10 | Schering Corporation | Substituierte anilinderivate als histamin-h3-antagonisten |
| JP2009521445A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ |
| US20070161578A1 (en) * | 2005-12-21 | 2007-07-12 | Hwa Joyce J | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist |
| US20070197590A1 (en) * | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| US7728031B2 (en) * | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| WO2008045564A2 (en) * | 2006-10-12 | 2008-04-17 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
| JP2010520201A (ja) * | 2007-03-02 | 2010-06-10 | シェーリング コーポレイション | ベンズイミダゾール誘導体およびその使用方法 |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| WO2009058348A1 (en) * | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| CN101910184A (zh) * | 2007-11-08 | 2010-12-08 | 西特里斯药业公司 | 可溶性噻唑并吡啶 |
| BRPI0820701A2 (pt) | 2007-12-11 | 2015-06-16 | Cytopathfinder Inc | Composto de carboxamida e seu uso como agonistas do receptor de quimiocina |
| EP3090739A1 (de) * | 2008-01-04 | 2016-11-09 | Schabar Research Associates LLC | Zusammensetzungen aus naproxen-natriumsalz und nizatidin |
| JP5628828B2 (ja) | 2008-12-19 | 2014-11-19 | サートリス ファーマシューティカルズ， インコーポレイテッド | チアゾロピリジンサーチュイン調節化合物 |
| EP2575815A4 (de) | 2010-06-04 | 2013-12-25 | Albany Molecular Res Inc | Glycin-transporter-1-hemmer, verfahren zu ihrer herstellung und ihre verwendung |
| JP2014114212A (ja) * | 2011-03-29 | 2014-06-26 | Dainippon Sumitomo Pharma Co Ltd | 新規ベンズイミダゾール誘導体 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| US11739070B2 (en) | 2018-01-19 | 2023-08-29 | Idorsia Pharmaceuticals Ltd. | C5A receptor modulators |
| CN114072407A (zh) | 2019-04-02 | 2022-02-18 | 阿里戈斯治疗公司 | 靶向prmt5的化合物 |
| US10639315B1 (en) | 2019-05-21 | 2020-05-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating Alzheimer's disease |
| US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
| US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
| US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
| US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
| US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
| US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
| US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
| US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
| JP2022536017A (ja) * | 2019-04-30 | 2022-08-12 | ラ ファーマテック インコーポレイテッド | 精神障害、行動障害、認知障害を処置する方法 |
| CN110105263A (zh) * | 2019-05-13 | 2019-08-09 | 常州大学 | 一种阿米卡星中间体的合成方法 |
| CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
| US12514846B2 (en) | 2020-07-15 | 2026-01-06 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach |
| IL299845A (en) | 2020-07-15 | 2023-03-01 | Schabar Res Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
| CN118019727A (zh) * | 2021-06-23 | 2024-05-10 | 豪夫迈·罗氏有限公司 | 用于制备nlrp3抑制剂的方法 |
| US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
| AU2023413741A1 (en) * | 2022-12-23 | 2025-02-20 | F. Hoffmann-La Roche Ag | Proccesses for the preparation of an nlrp3 inhibitor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0730037B2 (ja) | 1987-03-13 | 1995-04-05 | 第一製薬株式会社 | ピリミジニルプロピオン酸誘導体 |
| JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP3859738B2 (ja) * | 1993-05-26 | 2006-12-20 | 大日本住友製薬株式会社 | キナゾリノン誘導体 |
| FR2725986B1 (fr) * | 1994-10-21 | 1996-11-29 | Adir | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US5574044A (en) * | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
| CA2200468A1 (en) * | 1994-10-27 | 1996-05-09 | Wayne J. Thompson | Muscarine antagonists |
| GB9521781D0 (en) * | 1995-10-24 | 1996-01-03 | Merck Sharp & Dohme | Therapeutic agents |
| US6211199B1 (en) * | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| JPH11513991A (ja) * | 1995-11-17 | 1999-11-30 | ヘキスト・マリオン・ルセル・インコーポレイテツド | アレルギー性疾患の治療に有用な置換４−（１ｈ−ベンズイミダゾル−２−イル−アミノ）ピペリジン |
| PE100298A1 (es) | 1996-08-16 | 1999-01-11 | Schering Corp | Tratamiento de las respuestas alergicas de la vias respiratorias superiores |
| US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| DE19952146A1 (de) * | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| CN1461303A (zh) | 2000-09-20 | 2003-12-10 | 先灵公司 | 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑 |
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| MXPA03008356A (es) | 2001-03-13 | 2003-12-11 | Schering Corp | Compuestos del tipo no imidazol como antagonistas de histamina h3. |
| CA2444595A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| KR20040099449A (ko) * | 2002-04-18 | 2004-11-26 | 쉐링 코포레이션 | 히스타민 ｈ3 길항제로서의1-(4-피페리디닐)벤즈이미다졸론 |
-
2003
- 2003-04-16 KR KR10-2004-7016552A patent/KR20040099449A/ko not_active Ceased
- 2003-04-16 AT AT03719770T patent/ATE529112T1/de not_active IP Right Cessation
- 2003-04-16 US US10/414,943 patent/US7220735B2/en not_active Expired - Fee Related
- 2003-04-16 MY MYPI20031425A patent/MY132566A/en unknown
- 2003-04-16 PE PE2003000387A patent/PE20040464A1/es not_active Application Discontinuation
- 2003-04-16 WO PCT/US2003/011696 patent/WO2003103669A1/en not_active Ceased
- 2003-04-16 AR AR20030101341A patent/AR040406A1/es unknown
- 2003-04-16 CN CNB038137801A patent/CN100360130C/zh not_active Expired - Fee Related
- 2003-04-16 NZ NZ535764A patent/NZ535764A/en not_active IP Right Cessation
- 2003-04-16 JP JP2004510788A patent/JP4563800B2/ja not_active Expired - Fee Related
- 2003-04-16 CA CA002482551A patent/CA2482551C/en not_active Expired - Fee Related
- 2003-04-16 MX MXPA04010172A patent/MXPA04010172A/es active IP Right Grant
- 2003-04-16 AU AU2003223631A patent/AU2003223631B2/en not_active Ceased
- 2003-04-16 EP EP03719770A patent/EP1494671B1/de not_active Expired - Lifetime
- 2003-04-17 TW TW092108926A patent/TW200305409A/zh unknown
-
2004
- 2004-10-04 ZA ZA200407985A patent/ZA200407985B/xx unknown
- 2004-10-14 IL IL164583A patent/IL164583A/en not_active IP Right Cessation
-
2006
- 2006-03-22 JP JP2006079808A patent/JP2006206603A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL164583A (en) | 2010-05-17 |
| MY132566A (en) | 2007-10-31 |
| JP4563800B2 (ja) | 2010-10-13 |
| AU2003223631B2 (en) | 2006-07-20 |
| PE20040464A1 (es) | 2004-07-24 |
| US7220735B2 (en) | 2007-05-22 |
| CA2482551C (en) | 2009-08-11 |
| AU2003223631A1 (en) | 2003-12-22 |
| EP1494671A1 (de) | 2005-01-12 |
| AR040406A1 (es) | 2005-04-06 |
| TW200305409A (en) | 2003-11-01 |
| KR20040099449A (ko) | 2004-11-26 |
| CN100360130C (zh) | 2008-01-09 |
| WO2003103669A1 (en) | 2003-12-18 |
| JP2006206603A (ja) | 2006-08-10 |
| CN1658875A (zh) | 2005-08-24 |
| IL164583A0 (en) | 2005-12-18 |
| NZ535764A (en) | 2007-10-26 |
| JP2005529161A (ja) | 2005-09-29 |
| ZA200407985B (en) | 2005-10-19 |
| CA2482551A1 (en) | 2003-12-18 |
| MXPA04010172A (es) | 2005-02-03 |
| EP1494671B1 (de) | 2011-10-19 |
| US20040048843A1 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE529112T1 (de) | 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten | |
| ATE389406T1 (de) | 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten | |
| ATE344798T1 (de) | Als histamin-h3-antagonisten geeignete indolderivate | |
| ATE461191T1 (de) | N-substituierte 2-oxodihydropyridinderivate als npy antagonisten | |
| IS8509A (is) | Ný 2-heteróarýl-setin bensímídasól afleiða | |
| DE60330227D1 (de) | N3-alkylierte benzimidazol-derivate als mek-hemmer | |
| DK1571145T3 (da) | Substitueret piperidinforbindelser til anvendelse som H3 histaminreceptor-antagonister | |
| ATE450526T1 (de) | Als antagonisten von histamin h3 geeignete piperidinderivate | |
| NO20051871D0 (no) | Opioid reseptorantagonister | |
| DE60320933D1 (de) | Rho-kinase inhibitoren | |
| DE60331061D1 (de) | Heterozyklische vegfr-2 kinase inhibitoren | |
| DK1515969T3 (da) | Spiroindolinpiperidinderivater | |
| DE60320529D1 (de) | Chinolinderivate als npy antagonisten | |
| ATE370135T1 (de) | Substituierte piperidine als histamin-h3- rezeptorliganden | |
| NO20034840L (no) | Nedihulls verktoy | |
| ATE386518T1 (de) | Benzimidazolderivate | |
| ATE308543T1 (de) | Piperidinderivate | |
| ATE373654T1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
| DK1556370T3 (da) | Fremgangsmåde til syntese af en benzimidazol forbindelse | |
| ITMI20020942A0 (it) | Macchina di chiodatura | |
| ATE495168T1 (de) | Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten | |
| DE60322254D1 (de) | Imidazolderivate als faktor-xa-inhibitoren | |
| DE60336672D1 (de) | Harnstoffderivate als IL-8-Rezeptorantagonisten | |
| ATE497494T1 (de) | Substituierte benzimidazol-sulfonamid-derivate als breitspectrum hiv- protease- inhibitoren | |
| HK1067315A (en) | 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |